Considerations in Alzheimer's Disease in Women.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review methodology.
PubMed 42490036 · doi:10.1007/s11910-026-01504-3
What was done
This narrative review examined sex differences in Alzheimer's disease risk, clinical presentation, and biomarker trajectories, focusing on the roles of hormonal transitions, APOE genotype, biomarker dynamics (amyloid, tau, and plasma p-tau217), and their implications for clinical assessment and disease-modifying therapies.
What was found
The abstract reports no quantitative values or statistical effect sizes. Qualitatively, it notes that women represent nearly two-thirds of individuals with Alzheimer's disease. While amyloid accumulation trajectories appear similar between sexes, women exhibit earlier or greater tau deposition once amyloid pathology is established. The APOE ε4 allele confers greater risk in women, and vulnerability is compounded by menopause, adverse pregnancy outcomes, chronic stress, depression, and metabolic factors. Additionally, women maintain verbal memory performance longer than men despite advancing pathology, which can lead to delayed clinical diagnosis.
Why it matters
Understanding sex-specific biological differences and cognitive reserve patterns is critical for accurately interpreting plasma biomarkers, timing diagnostic interventions, and optimizing treatment with emerging disease-modifying therapies.
Limits
The abstract describes a narrative review and presents no original empirical data, sample size details, or quantitative synthesis. It does not provide specific effect sizes or statistical comparisons for the described biomarker and cognitive differences.
Cited by
- supports Two-thirds of the people diagnosed with Alzheimer's disease are women.